Journal of Clinical Oncology - ASCO Publications
Jan 2, 2025 · Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and …
JCO Precision Oncology - ASCO Publications
Dec 18, 2024 · JCO Precision Oncology (JCO PO) is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science …
ASCO Publications
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of …
ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline May 17, 2024. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor …
JCO Global Oncology - ASCO Publications
Jan 9, 2025 · Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and …
Treatment and outcomes of goblet cell adenocarcinomas (GCAs) …
Jan 20, 2015 · Background: GCAs are rare mucinous neoplasms with mixed epithelial and endocrine differentiation, which behave more like mucinous adenocarcinomas than …
Management of Immune-Related Adverse Events in Patients …
Immunotherapy has revolutionized the treatment of many different types of cancers. Immune checkpoint inhibitors (ICPis) targeting cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), …
Does size matter? Lesion size as an indicator of number of cores …
Feb 19, 2020 · Background: MRI/US fusion guided prostate biopsy (FBx) has been shown to detect clinically significant prostate cancer (csCaP) at higher rates and with fewer cores than …
Nov 1, 2021 · ASCO special articles Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
ASCO Daily News
The treatment landscape for hormone receptor–positive, HER2-negative metastatic breast cancer has significantly changed over the last 5 years with recent approvals of biomarker-guided …